📊 PRAX Key Takeaways
Is Praxis Precision Medicines, Inc. (PRAX) a Good Investment?
Praxis is a pre-revenue clinical-stage pharmaceutical company burning $86.2M annually with zero product sales, despite maintaining a strong $536.3M cash position and debt-free balance sheet. While balance sheet strength provides approximately 6+ years of cash runway, the complete absence of revenue, substantial operating losses, and typical biotech development risk profile warrant caution without demonstrated clinical trial success or near-term regulatory pathways.
Praxis Precision Medicines, Inc. Key Strengths (PRAX)
- Strong balance sheet: $1.4B stockholders equity with zero debt
- Exceptional liquidity: 15.88x current ratio ensures financial flexibility
- Substantial cash reserves: $536.3M provides multi-year operational runway
PRAX Stock Risks: Praxis Precision Medicines, Inc. Investment Risks
- Zero revenue: no approved products or commercial viability demonstrated
- Severe cash burn: -$86.2M operating cash flow annually creates development risk
- Biotech execution risk: high probability of clinical trial failure typical in pharmaceutical R&D
- Negative profitability: -$105.9M operating loss with negative ROE/ROA
- Limited insider confidence: only 2 Form 4 filings in 90 days suggests minimal insider buying support
Key Metrics to Watch
- Quarterly operating cash burn rate and cash runway extension
- Clinical trial progress and regulatory milestone announcements
- Changes in R&D spending and pipeline advancement stage
Praxis Precision Medicines, Inc. (PRAX) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 15.88x current ratio provides a solid financial cushion.
PRAX Profit Margin, ROE & Profitability Analysis
PRAX vs Healthcare Sector: How Praxis Precision Medicines, Inc. Compares
How Praxis Precision Medicines, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Praxis Precision Medicines, Inc. Stock Overvalued? PRAX Valuation Analysis 2026
Based on fundamental analysis, Praxis Precision Medicines, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Praxis Precision Medicines, Inc. Balance Sheet: PRAX Debt, Cash & Liquidity
PRAX Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Praxis Precision Medicines, Inc.'s revenue has grown significantly by 250% over the 5-year period, indicating strong business expansion. The most recent EPS of $-18.69 indicates the company is currently unprofitable.
PRAX Revenue Growth, EPS Growth & YoY Performance
PRAX Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | N/A | -$32.7M | $-2.75 |
| Q2 2025 | N/A | -$32.7M | $-1.74 |
| Q1 2025 | N/A | -$39.6M | $-2.84 |
| Q3 2024 | $302.0K | -$24.6M | $-2.72 |
| Q2 2024 | $357.0K | -$32.7M | $-1.74 |
| Q1 2024 | $431.0K | -$37.5M | $-2.84 |
| Q3 2023 | N/A | -$24.6M | $-0.18 |
| Q2 2023 | N/A | -$34.3M | $-0.49 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Praxis Precision Medicines, Inc. Dividends, Buybacks & Capital Allocation
PRAX SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Praxis Precision Medicines, Inc. (CIK: 0001689548)
📋 Recent SEC Filings
❓ Frequently Asked Questions about PRAX
What is the AI rating for PRAX?
Praxis Precision Medicines, Inc. (PRAX) has an AI grade of C with 75% confidence, based on fundamental analysis of SEC EDGAR filings.
What are PRAX's key strengths?
Claude: Strong balance sheet: $1.4B stockholders equity with zero debt. Exceptional liquidity: 15.88x current ratio ensures financial flexibility.
What are the risks of investing in PRAX?
Claude: Zero revenue: no approved products or commercial viability demonstrated. Severe cash burn: -$86.2M operating cash flow annually creates development risk.
What is PRAX's revenue and growth?
Praxis Precision Medicines, Inc. reported revenue of $0.0.
Does PRAX pay dividends?
Praxis Precision Medicines, Inc. does not currently pay dividends.
Where can I find PRAX SEC filings?
Official SEC filings for Praxis Precision Medicines, Inc. (CIK: 0001689548) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is PRAX's EPS?
Praxis Precision Medicines, Inc. has a diluted EPS of $-3.20.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is PRAX's fundamental grade?
Based on our AI fundamental analysis in June 2026, Praxis Precision Medicines, Inc. has a C grade with 75% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is PRAX stock overvalued or undervalued?
Valuation metrics for PRAX: ROE of -6.6% (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is PRAX's AI grade for 2026?
Our dual AI analysis gives Praxis Precision Medicines, Inc. a combined C grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is PRAX's free cash flow?
Praxis Precision Medicines, Inc.'s operating cash flow is $-86.2M, with capital expenditures of $62.0K.
How does PRAX compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE -6.6% (avg: 15%), current ratio 15.88 (avg: 2).